Approaches and Challenges in SARS-CoV-2 Vaccine Development

The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagotto, Gabriel, Yu, Jingyou, Barouch, Dan H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416703/
https://www.ncbi.nlm.nih.gov/pubmed/32798444
http://dx.doi.org/10.1016/j.chom.2020.08.002
_version_ 1783569348941578240
author Dagotto, Gabriel
Yu, Jingyou
Barouch, Dan H.
author_facet Dagotto, Gabriel
Yu, Jingyou
Barouch, Dan H.
author_sort Dagotto, Gabriel
collection PubMed
description The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection.
format Online
Article
Text
id pubmed-7416703
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-74167032020-08-10 Approaches and Challenges in SARS-CoV-2 Vaccine Development Dagotto, Gabriel Yu, Jingyou Barouch, Dan H. Cell Host Microbe Perspective The explosive spread of SARS-CoV-2 suggests that a vaccine will be required to end this global pandemic. Progress in SARS-CoV-2 vaccine development to date has been faster than for any other pathogen in history. Multiple SARS-CoV-2 vaccine candidates have been evaluated in preclinical models and are currently in clinical trials. In this Perspective, we discuss three topics that are critical for SARS-CoV-2 vaccine development: antigen selection and engineering, preclinical challenge studies in non-human primate models, and immune correlates of protection. Elsevier Inc. 2020-09-09 2020-08-10 /pmc/articles/PMC7416703/ /pubmed/32798444 http://dx.doi.org/10.1016/j.chom.2020.08.002 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Perspective
Dagotto, Gabriel
Yu, Jingyou
Barouch, Dan H.
Approaches and Challenges in SARS-CoV-2 Vaccine Development
title Approaches and Challenges in SARS-CoV-2 Vaccine Development
title_full Approaches and Challenges in SARS-CoV-2 Vaccine Development
title_fullStr Approaches and Challenges in SARS-CoV-2 Vaccine Development
title_full_unstemmed Approaches and Challenges in SARS-CoV-2 Vaccine Development
title_short Approaches and Challenges in SARS-CoV-2 Vaccine Development
title_sort approaches and challenges in sars-cov-2 vaccine development
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416703/
https://www.ncbi.nlm.nih.gov/pubmed/32798444
http://dx.doi.org/10.1016/j.chom.2020.08.002
work_keys_str_mv AT dagottogabriel approachesandchallengesinsarscov2vaccinedevelopment
AT yujingyou approachesandchallengesinsarscov2vaccinedevelopment
AT barouchdanh approachesandchallengesinsarscov2vaccinedevelopment

Ejemplares similares